FDA Clearance Tracker · P160048
EVERSENSE CONTINUOUS GLUCOSE MONITORING SYSTEM
Last checked: Nov 19, 2026Latest source record: Jun 21, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Jun 21, 2018
Approved
Time to decision
603 days
Received Oct 26, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P160048
- Device name
- EVERSENSE CONTINUOUS GLUCOSE MONITORING SYSTEM
- Applicant
- Senseonics, Incorporated
- Applicant location
- Germantown, MD
- Received
- Oct 26, 2016
- Decided
- Jun 21, 2018
- Decision
- Approved
- Supplements
- 28 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for The Eversense CGM System. The device is indicated for continually measuring glucose levels in adults (18 years and older) with diabetes for up to 90 days.The system is intended to:1) Provide real-time glucose readings;2) Provide glucose trend information; and3) Provide alerts for the detection and prediction of episodes of low blood glucose (hypoglycemia) and high blood glucose (hyperglycemia).The system is a prescription device. Historical data from the system can be interpreted to aid in providing therapy adjustments. These adjustments should be based on patterns seen over time.The system is indicated for use as an adjunctive device to complement, not replace, information obtained from standard home blood glucose monitoring devices.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code QCD (Continuous glucose monitor, implanted, adjunctive use).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Senseonics, Incorporated
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K241335 · Decided Sep 16, 2024 · 126 days after receipt
Device type: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA) · Laboratory Medicine & Pathology
- Eversense AP CGM SystemNew device typeDe Novo
DEN230052 · Decided Apr 29, 2024 · 264 days after receipt
Device type: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA) · Laboratory Medicine & Pathology
- Eversense® E3 Continuous Glucose Monitoring (CGM) SystemPMA supplement
P160048-S021 · Decided Mar 29, 2023 · 180 days after receipt · Panel Track
Device type: Sensor, glucose, implanted, non-adjunctive use (QHJ) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.